Home
Random
Nearby
Log in
Settings
Donate
About Wikidata
Disclaimers
Search
(Q53202995)
Watch
English
Intensified chemotherapy for diffuse large B-cell lymphomas.
scientific article published in November 2011
In more languages
edit
Statements
instance of
scholarly article
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22118432
retrieved
12 May 2018
reference URL
http://europepmc.org/abstract/MED/22118432
title
Intensified chemotherapy for diffuse large B-cell lymphomas.
(English)
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22118432
retrieved
12 May 2018
reference URL
http://europepmc.org/abstract/MED/22118432
main subject
chemotherapy
1 reference
based on heuristic
inferred from title
author
Julie M Vose
series ordinal
1
object named as
Julie M Vose
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22118432
retrieved
12 May 2018
reference URL
http://europepmc.org/abstract/MED/22118432
language of work or name
English
0 references
publication date
1 November 2011
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22118432
retrieved
12 May 2018
reference URL
http://europepmc.org/abstract/MED/22118432
published in
The Lancet
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22118432
retrieved
12 May 2018
reference URL
http://europepmc.org/abstract/MED/22118432
volume
378
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22118432
retrieved
12 May 2018
reference URL
http://europepmc.org/abstract/MED/22118432
issue
9806
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22118432
retrieved
12 May 2018
reference URL
http://europepmc.org/abstract/MED/22118432
page(s)
1828-1829
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22118432
retrieved
12 May 2018
reference URL
http://europepmc.org/abstract/MED/22118432
cites work
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961269-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961269-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961269-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961269-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961269-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Double-hit B-cell lymphomas
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961269-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961269-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961269-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961269-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers
1 reference
stated in
Crossref
reference URL
https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961269-5
retrieved
7 January 2021
based on heuristic
inferred from DOI database lookup
Identifiers
DOI
10.1016/S0140-6736(11)61269-5
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22118432
retrieved
12 May 2018
reference URL
http://europepmc.org/abstract/MED/22118432
PubMed publication ID
22118432
1 reference
stated in
Europe PubMed Central
PubMed publication ID
22118432
retrieved
12 May 2018
reference URL
http://europepmc.org/abstract/MED/22118432
Sitelinks
Wikipedia
(0 entries)
edit
Wikibooks
(0 entries)
edit
Wikinews
(0 entries)
edit
Wikiquote
(0 entries)
edit
Wikisource
(0 entries)
edit
Wikiversity
(0 entries)
edit
Wikivoyage
(0 entries)
edit
Wiktionary
(0 entries)
edit
Multilingual sites
(0 entries)
edit
